PROTECT VIII Kids: BAY 94‐9027 (PEGylated Recombinant Factor VIII) safety and efficacy in previously treated children with severe haemophilia A

INTRODUCTION: BAY 94‐9027, a site‐specifically PEGylated, B‐domain‒deleted recombinant factor VIII (FVIII) with extended half‐life, demonstrated efficacy for bleed prevention and treatment in previously treated adolescents and adults with severe haemophilia A. AIM: To assess BAY 94‐9027 in children...

Descripción completa

Detalles Bibliográficos
Autores principales: Santagostino, Elena, Kenet, Gili, Fischer, Kathelijn, Biss, Tina, Ahuja, Sanjay, Steele, MacGregor, Martínez, M., Male, C., van Geet, C., Mondelaers, V., Kaleva, V., Stoyanova‐Deleva, A., Bobev, D., Blanchette, V., Zanon, E., Gagliano, F., Rageliene, L., Peters, M., Mlynarski, W., Badowska, W., Serban, M., Rusen, L., Uscatescu, V., Will, A., Payne, J., Tunstall, O., Kerlin, B., Gruppo, R., Eyster, M. E., Ducore, J., Schwartz, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317355/
https://www.ncbi.nlm.nih.gov/pubmed/32212300
http://dx.doi.org/10.1111/hae.13963

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317355/
https://www.ncbi.nlm.nih.gov/pubmed/32212300
http://dx.doi.org/10.1111/hae.13963

Ejemplares similares